11/07/2013 18:45:00

U.K. Recalls Drugs Made in India

LONDON--In another sign of possible manufacturing problems in India's pharmaceutical industry, the U.K.'s medicines regulator said it was recalling 16 drugs made by Wockhardt Ltd. (532300.BY) after finding "manufacturing deficiencies" at one of the company's factories in India.

The Medicines and Healthcare products Regulatory Agency, or MHRA, called it a "precautionary recall," as there is no evidence that the medicines are defective. The agency said it is recalling the drugs from pharmacies and wholesalers but isn't asking patients to return their Wockhardt medicines.

"There is no evidence of a patient safety risk. ...however, the MHRA has to act in the interest of public health as poor manufacturing standards cannot be allowed to continue," the agency said.

The recalled drugs, manufactured in the central Indian city of Waluj, include treatments for infections, hypertension, diabetes, epilepsy and other diseases. The MHRA said the plant suffered from "poor cleaning practices" and defective ventilation systems. The agency inspection also found evidence of "forged documents relating to staff training records."

In an emailed statement, Wockhardt confirmed the news and said the recall would result in a one-time charge of 1.5 million pounds ($2.25 million) this year. Exports from the Waluj plant constitute less than 5% of the company's total U.K. sales and less than 2% of overall sales, it added.

It was the second recent setback for the company and its Waluj factory. In May, the U.S. Food and Drug Administration imposed an import ban on products from the factory after it failed an FDA safety inspection. The FDA didn't elaborate on the problems it found.

In a conference call at the time, Wockhardt Chairman Habil Khorakiwala said the company was implementing "corrective measures to be in compliance with the FDA guidelines." He said the U.S. import ban could cost the company $100 million in revenue this fiscal year. Wockhardt generated total revenue of 25.6 billion rupees ($460.6 million) in the year ended March 31, 2012.

Also in May, India's Ranbaxy Laboratories Ltd. (500359.BY) agreed to pay $500 million in civil and criminal fines for exporting adulterated drugs to the U.S.

In a phone interview Thursday, D.G. Shah, secretary-general of the Indian Pharmaceutical Alliance, an industry body, said the group has written to the FDA asking it to conduct workshops with Indian companies to correct erroneous practices.

"Companies need to better understand FDA processes, and there needs to be a correction in their organizational culture, right from drug discovery to development and production," Mr. Shah said.

Write to Jeanne Whalen at jeanne.whalen@wsj.com and Anirban Chowdhury at anirban.chowdhury@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 11, 2013 13:45 ET (17:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Feb
 
En debat i forum i dag løb lidt af vejen, og moderator måtte slette rigtig mange indlæg ”fordi indlæ..
137
14 Feb
VWS
Nu har jeg haft lidt tid til at kigge på det nyligt offentliggjorte regnskab for 2016. Baseret på de..
82
14 Feb
FING-B
Investering er umiddelbart blevet til en vittighed. Før i tiden investerede man i et selskab, man tr..
26
18 Feb
OMXC25
Den rammer da noglenlunde godt.      http://finans.dk/live/opinion/ECE9365426/den-stoerste-trussel-m..
25
15 Feb
FING-B
erikanthon .... ANON ....   Nu er det da vist tiden, at du får et lødigt, ud fra den viden jeg har. ..
25
14 Feb
E:PROTCT
  Jeg har flere gange analyseret det norske forsikringsselskab, Protector, som er et yderst interess..
23
13 Feb
NOVO-B
det er grundlæggende noget vrøvl. Aktilbagekøb mindsker risikoen i en aktie fordi de kortsigtede uds..
15
18 Feb
OMXC25
tonnio: Jeg er ikke i tvivl om, at et meget stort flertal af danskerne ville have stemt ja, til at v..
14
15 Feb
PNDORA
Tak for det svinske svar. Det gav mig muligheden for at se hvor jeg havde misforstået regnestykket. ..
14
17 Feb
 
omglol,   Hvis du er valueinvestor, er Maj Invests Kurt Karas spritnye: "Den rationelle investor" en..
13

Form 8.5 (EPT/RI) - E2V Technologies plc

07/02/2017 07:47:25
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY ..

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

06/02/2017 15:31:59
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECU..

Alliance Trust PLC : Transaction in Own Shares

06/02/2017 07:00:03
6 February 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 3 February 2017 the Comp..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
JACC: Clinical Electrophysiology Manuscript Featuring BioSig's PURE EP System in Top Five Most Influential of 2016
2
JACC: Clinical Electrophysiology Manuscript Featuring BioSig’s PURE EP System in Top Five Most Influential of 2016
3
BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2016
4
Impinj and STANLEY Healthcare Announce Partnership and Platform Integration
5
Thinfilm Completes Purchase of EAS Manufacturing Equipment for Roll-to-Roll Line

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 February 2017 15:30:31
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170217.2 - EUROWEB7 - 2017-02-20 16:30:31 - 2017-02-20 15:30:31 - 1000 - Website: OKAY